Skip to main content
. 2021 Jun 25;100(25):e26285. doi: 10.1097/MD.0000000000026285

Table 2.

VCY and %PY with viral load >200 or >50 copies/mL by participant characteristics, the HIV Outpatient Study, 1995–2016 (N = 1645).

Characteristics median (IQR), or N (column %) Overall (n= 1645) VCY, log10 copy-years P %PY with viral load >200 copies/mL P %PY with viral load > 50 copies/mL P
All participants 1645 (100.0) 3.0 (2.3–4.2) 9.7 (0.9–46.7) 25.5 (6.0–72.0)
Age, y <.001 <.001 <.001
 <35 630 (38.3) 3.0 (2.2–4.3) 12.4 (0.8–58.8) 29.0 (7.2–80.1)
 35–45 557 (33.9) 3.2 (2.4–4.4) 12.2 (1.8–45.8) 27.7 (8.4–76.8)
 >45 458 (27.8) 2.7 (2.1–3.7) 6.1 (0.0–28.7) 19.1 (3.8–52.2)
Sex .019 <.001 <.001
 Male 1289 (78.4) 3.0 (2.2–4.1) 8.0 (0.6–41.3) 23.6 (5.5–67.7)
 Female 356 (21.6) 3.1 (2.4–4.5) 18.0 (2.4–63.1) 35.9 (9.1–86.7)
Race/ethnicity <.001 <.001 <.001
 Non-Hispanic/Latino white 743 (45.2) 3.0 (2.2–4.1) 6.2 (0.7–30.6) 20.1 (4.4–58.0)
 Non-Hispanic/Latino black 606 (36.8) 3.1 (2.4–4.5) 18.0 (2.3–66.4) 35.9 (12.6–86.8)
 Hispanic/Latino ethnicity 224 (13.6) 2.9 (2.2–4.2) 9.0 (0.3–41.8) 24.1 (4.7–66.4)
 Other race/ethnicity 72 (4.4) 2.5 (2.1–3.5) 5.3 (0.0–21.1) 17.4 (3.6–40.9)
HIV risk activity <.001 <.001 <.001
 MSM 929 (56.5) 2.9 (2.2–4.0) 6.0 (0.5–30.7) 19.1 (4.4–56.0)
 PWID 90 (5.5) 3.1 (2.4–4.6) 23.9 (3.7–74.1) 46.7 (15.8–92.2)
 Heterosexual 525 (31.9) 3.1 (2.4–4.4) 19.3 (2.9–64.4) 36.3 (12.4–85.6)
 Unknown/other risk 101 (6.1) 3.3 (2.3–4.5) 12.1 (0.0–57.5) 26.8 (4.2–82.5)
Payer .42 <.001 <.001
 Private 882 (53.6) 2.9 (2.2–4.1) 6.5 (0.5–33.0) 20.2 (4.5–60.1)
 Public 506 (30.8) 3.0 (2.2–4.4) 18.6 (1.5–62.4) 35.4 (10.8–86.1)
 None/unknown/other 257 (15.6) 3.1 (2.4–4.1) 12.5 (2.0–48.4) 28.6 (10.3–75.0)
Died <.001 <.001 <.001
 Yes 115 (7.0) 3.7 (2.7–4.9) 44.1 (11.8–91.6) 81.9 (26.2–100.0)
 No 1530 (93.0) 2.9 (2.2–4.2) 8.5 (0.6–41.9) 23.8 (5.5–66.7)

%PY = percent person-years, IQR = interquartile range, MSM = men who have sex with men, PWID = persons who inject drugs, VCY = viremia copy-years.

Characteristics are summarized at baseline (defined as the date 6 months after cART initiation), unless otherwise indicated.

Wilcoxon rank-sum tests for continuous variables, Yates-corrected chi-square test for categorical variables.